



Evaluation of Engraftment and Adverse Effects of Granulocyte Colony Stimulating Factor versus PEG Granulocyte Colony Stimulating Factor in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation

Mahshid Mehdizadeh^{a,b}, Maria Tavakoli-Aradakani^{c,d}, Shayan Zamani^e, Gholamreza Zamani^f, Naeem Nikpour^{g*}

^aTaleghani Hospital Research Development Committee, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ^bHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ^cDepartment of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ^dPharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, ^eStudents' Scientific Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, ^fDepartment of Pediatric Neurology, Childrens' Medical Center, Tehran University of Medical Sciences, Tehran, Iran, ^gDepartment of Hematology and Oncology, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran.

Abstract

Hematopoietic stem cell transplantation (HSCT) is an effective treatment for many hematological malignancies. Engraftment is the foremost step in the autologous hematopoietic stem cell transplantation (AHSCT) process in which different granulocyte colony-stimulating factors with various administrations are used. In this study, we evaluated and compared the efficacy and side effects of two forms of recombinant granulocyte colony-stimulating growth factors (G-CSF), G-CSF and Peg G-CSF. In this randomized clinical trial, 60 consecutive patients with multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma who underwent AHSCT were included, the average age of the patients was 55; the patients were then divided into two groups so the comparison of efficacy and side effects between the two methods become achievable. The local ethical committee approved the study with the code of SB2019:210291, and the Helsinki declaration was respected across the study. In the first group, patients received peg G-CSF at a dose of 6 mg on day five, and the second group received G-CSF started with 5 µg/kg from day 5. We compared engraftment time and adverse effects in the two groups. Our study demonstrated no difference between the two groups regarding need for transfusion and infection complications; also, the two groups did not differ in terms of the flue-like syndrome, the type of infection and the recorded number of febrile neutropenia. Mean leukocyte engraftment days were 10.97 ± 1 and 11.1 ± 1.1 that was similar in both groups ($P=0.328$). Mean platelet engraftment days were 11.03 ± 2.4 and 11.1 ± 2.4 without significant difference ($P=0.714$). It was concluded that *Pegfilgrastim* has the same efficacy and safety profile in comparison to *Filgrastim*. Therefore, since *Pegfilgrastim* has an easier method of injection and can simplify the HSCT process.

Keywords: Stem Cell Transplantation, G-CSF, PEG-G-CSF, Engraftment, Adverse Effect, Autologous, HSCT.

Corresponding Author: Naeem Nikpour, Department of Hematology and Oncology, Shahid Bahonar Hospital, Kerman University of Medical Sciences, Kerman, Iran.

Tel: (+98)9133415761

Email: dr.nikpour1360@yahoo.com

Cite this article as: Mehdizadeh M, Tavakoli-Aradakani M, Zamani S, Zamani G, Nikpour N, Evaluation of Engraftment and Adverse Effects of Granulocyte Colony Stimulating Factor versus PEG Granulocyte Colony Stimulating Factor in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation, 2021, 17 (1): 99-106.

1. Introduction

Hematopoietic stem cell transplantation (HSCT) would result in more prolonged survival rates in certain types of hematologic malignancies, but bone marrow suppression and need for cellular replacement are amongst important debates. Progenitor stem cells are an important integrated part of this life saving process. Granulocyte-colony stimulating factor (G-CSF) is a critical cytokine affecting releasing and homing of hematopoietic stem cells; two recombinant types of the very mentioned are GCSF and Peg-GCSF [1-6] GCSF is usually prescribed daily due to its short half-life of 3-4 hours, whilst Peg-GCSF which is prescribed for a single dose based on its long half-life of two weeks [7-10]. This drug is used as an adjuvant therapy short-after stem cells transfusion to shorten the duration of severe neutropenia and decrease the infectious side effects [11, 12]. Different types of GCSF with various injection methods have been used in HSCT setting, also in some studies, different doses are evaluated. Generally; GCSF is the drug of choice in HSCT setting after stem cell infusion. Some evidence has shown that single dose injection of PEG-GCSF may have good

efficacy and outcomes in stem cells' engraftment in autologous HSCT [12-15]. Since the Pegylated form is only injected once and has the benefit of a more long-lasting effect due to its longer half-life it may facilitate the HSCT process for the patients. Our study purpose was to compare the effects of short-acting routine form of GCSF versus PEG-GCSF in HSCs engraftment in transplantation process alongside considering the pharmaceutical adverse effects in Taleghani BMT center in Tehran.

2. Materials and Methods

In this randomized clinical trial, 60 consecutive patients with multiple myeloma, Hodgkin's, and non-Hodgkin's lymphoma with an average age of 55 (24-65 years), who underwent autologous hematopoietic stem cell transplantation (HSCT) were divided into two groups. The local ethical committee approved the study with the code of SB2019:210291, and the Helsinki declaration was respected across the study. Also, the informed consent form was received from all patients. All the patients who were eligible for AHSCT between 18-70 years old entered the study. According to ECOG criteria, inclusion criteria were patients needing to AHSCT (multiple myeloma Hodgkin and non-Hodgkin lymphoma) and optimal performance. The exclusion criteria were patients with inappropriate performance and lack of desire for participation in the study. Eligible patients initially underwent stem cell harvesting and received conditioning chemotherapy with routine protocols in the

HSCT ward and then were randomly divided into two groups. In the first group, patients received PEG-GCSF (Pegagen®) at a dose of 6 mg subcutaneously on days +5 and +9, the second group received GCSF 5µg/kg IV infusion during 20 minutes from day +5. Patients who didn't have any increase in White blood cell count after day +10, the dose of GCSF was doubled. Both study groups were assessed for engraftment of WBC, RBC and platelets. Side effects according to NCI (national cancer institute) toxicity grading were also recorded. The same physician checked all patients for complications (fever, headache, flue-like, etc.). CBC and kidney function tests were evaluated daily, liver function tests were measured three times per week. Engraftment day was determined the day in which a platelet count $>20000/u$ and absolute neutrophil count $> 500/\mu l$ were detected from the patient, and the duration of admission was calculated from the admission day to the day of discharge. Data analysis was done by SPSS version 25.0 software. The used tests were Kolmogorov-Smirnov, Independent-Sample-T, Fisher, Chi-Square, Man-Whitney, and Repeated-Measure-ANOVA. The P values less than 0.05 were considered statistically significant.

3. Results and Discussion

From Sep 2017 to May 2018, 68 patients enrolled in the study. Sixty patients were divided into two groups and 8 patients were excluded from the study. Demographic and background data are demonstrated in Table 1.

The disease's remission status was similar in both groups ($P=0.216$). The bone marrow status was the same ($P=0.157$). Eight patients (26.7%) in the Peg-GCSF group and one patient (3.3%) in the GCSF group had radiation therapy history showing a significant difference ($P=0.026$). No patients were using myelotoxic agents. No patient had a headache. The flu-like syndrome has differed across the groups ($P=0.024$), and all six subjects with this side effect were in the GCSF group. Bone pain ($P=0.197$) and fever ($P=0.243$) were the same across the groups (Table2). The mean febrile days were 6.3 ± 4.3 days and 2.4 ± 1.7 in GCSF and peg_GCSF groups respectively with a significant difference ($P=0.022$). Infection rate and transfusion requirements were similar between the groups ($P > 0.05$). The number of used packed cells were alike across the groups ($P=0.144$). The mean required platelet infusions were $9 \pm 6s.04$ and 7.1 ± 5.4 , in GCSF and peg_GCSF groups respectively which was the same across the groups ($P=0.354$).

The mean leukocyte engraftment days were 10.97 ± 1 and 11.1 ± 1.1 that was alike across the groups ($P=0.328$). The mean platelet engraftment days were 11.03 ± 2.4 and 11.1 ± 2.4 without a difference ($P=0.714$). Antibiotic usage was the same across the groups ($P=0.243$). The mean duration of antibiotic use was 6 ± 3.7 and 4 ± 2.5 days in GCSF and peg_GCSF groups respectively without a difference ($P=0.263$).

In this study, Peg GCSF and GCSF showed no difference in mean leukocyte engraftment

days that was 10.97 ± 1 and 11.1 ± 1.1 respectively in two groups, and mean platelet engraftment days were 11.03 ± 2.4 and 11.1 ± 2.4 without a difference. Also, the need for transfusion and the infection complication were the same, and the two groups did not differ in terms of the flu-like syndrome, the type of infection, the duration of febrile neutropenia. The total cost for peg-GCSF was lower than GCSF in this study. One of our goals was to reduce the job burden of our nurses; replacing the traditional form of GCSF with its pegylated form helped us through reaching our goal as it needed only two single doses in comparison to GCSF which needed daily injections with same results for platelet and leukocyte engraftment. Vanstraelen *et al.* assessed 20 consecutive patients with lymphoma or multiple myeloma receiving a single 6-mg dose of Peg GCSF on day one post-transplant to a historical control group of 60 patients receiving daily GCSF 5 microgram/kg starting on day one post-transplant similarly and reported no difference in neutrophil engraftment or fever between two drugs [12]. In another study by Mathew *et al.*, among 164 patients in two groups of Peg GCSF and GCSF, it was found that Peg GCSF led to faster engraftment, lower febrile neutropenia, and low antibiotic-therapy days [13]. However, in our study, engraftment and antibiotic use were similar between the groups, and only febrile days were different. In another study by Martino *et al.* Peg GCSF use resulted in 961USD cost-saving per patient [14]. Although the exact cost effectiveness evaluation was not

included in our study but it seems that it could be a positive point in peg -GCSF usage in HSCT setting. Probability to cost saving were also seen in our study. A comparative study by Green *et al.* of Peg GCSF versus GCSF showed that fever and infections were the same across the groups. Nevertheless, in our study, the febrile days showed a significant difference ($P=0.022$) [15]. In other studies, Peg GCSF single dose and GCSF, multiple doses had the same safety profile, but the duration of febrile neutropenia and total length of febrile days have differed as well as our study [16,17]. The infection rate has differed between groups in the study, but it has differed in our study. This difference may be due to various antibiotic protocols in different studies. Jagasia *et al.* [16] reported no side effects among 28 patients who received Peg GCSF and the GCSF and Peg GCSF groups. Neutrophil engraftment has differed between groups [16,17]. However, similar to our study the adverse effects were the same. For this matter selection of treatment for each patient is case-dependent. Vanstraelen *et al.* reported no difference between Peg GCSF and GCSF for fever and infection [12].

4. Conclusion

In our study, Peg GCSF showed similar efficacy and safety comparable with GCSF considering easier process for both patients and nurses. However, in our study, GCSF doses were prescribed in the 5th and 9th days, and in the majority of other studies, the first and fifth days were considered. Based on the obtained results, it may be concluded that GCSF and

Peg-GCSF have the same efficacy in engraftment after high dose chemotherapy however, further studies with larger sample size and multi-center sampling would develop more definite results.

Acknowledgments

We would like to thank our dear nurses and staff in Taleghani BMT center especially Mrs. Zeinab Kaboli for their sincere care for our patients.

References

- [1] Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J. Clin. Oncol.* (2006) 24:3187-205.
- [2] Chua HL, Plett PA, Sampson CH, Katz BP, Carnathan GW, MacVittie TJ et al. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. *Health. Phys.* (2014) 106:21-38.
- [3] Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. *Anticancer Drugs.* (2003) 14:259-64.
- [4] Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. *Semin. Oncol.* (2004) 31:27-34.
- [5] Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U et al. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. *Br. J. Haematol.* (2006) 133:533-7.
- [6] Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. *Haematologica* (2005) 90:225-231.
- [7] Nosari A, Cairoli R, Ciapanna D, Gargantini L, Intropido L, Baraté Cet al. Efficacy of single dose pegfilgrastim in enhancing the mobilization of CD34+ peripheral blood stem cells in aggressive lymphoma patients treated with cisplatin-aracytin-containing regimens. *Bone Marrow Transplant.* (2006) 38:413-6.
- [8] Willis F, Woll P, Theti D, Jamali H, Bacon P, Baker N et al. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumors. *Bone Marrow Transplant.* (2009) 43:927-34.
- [9] Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. *Transfusion.* (2006) 46:180-5.
- [10] Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. *Bone Marrow Transplant.* (2007) 39:743-50.
- [11] Putkonen M, Rauhala A, Pelliniemi TT, Remes K. Single-dose Pegfilgrastim is comparable to daily Filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. *Ann. Hematol.* (2009) 88:673-80.
- [12] Vanstraelen G, Frère P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. *Exp. Hematol.* (2006) 34:382-8.
- [13] Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL et al. Retrospective comparison of the effects of Filgrastim and Pegfilgrastim on the pace of engraftment in auto-SCT patients. *Bone Marrow Transplant.* (2010) 45:1522-7.

[14] Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G et al. Pegfilgrastim compared with Filgrastim after high-dose Melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. *Eur. J. Haematol.* (2006) 77:410-5.

[15] Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P et al. International Pegfilgrastim 749 Study Group: a randomized double-blind multicenter phase III study of fixed-dose single-administration Pegfilgrastim versus daily Filgrastim in patients receiving myelosuppressive chemotherapy. *Ann. Oncol.* (2003) 14:29-35.

[16] Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. *Bone Marrow Transplant.* (2005) 35:1165-9.

[17] Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F et al. Pegfilgrastim appears equivalent to daily dosing of Filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. *Clin. Lymphoma Myeloma Leuk.* (2010) 10:186-91.

Tables:**Table 1.** Demographic and background data of included cases.

Variable		PEG-GCSF Group	GCSF Group	P-value
Age		60.5 ± 13.4	50.5 ± 13.4	0.135
Sex	Male	18 (60%)	16 (53.3%)	0.602
	Female	12(40%)	14(46.7%)	
Chemotherapy courses number		1.4 ± 0.7	1.7 ± 0.8	0.124
Background disease	Multiple Myeloma	21 (70%)	20 (66.7%)	0.817
	Hodgkin Disease	5 (16.7%)	7 (23.3%)	
	Ewing Sarcoma	1 (3.3%)	1 (3.3%)	
	Non-Hodgkin lymphoma	2 (6.7%)	1 (3.3%)	
	T Cell Lymphoma	1 (3.3%)	1 (3.3%)	
CD34+ cells dose (10 ⁶ /kg)		4.1 ± 2.6	3.6 ± 3.02	0.136

Table 2. Complications of the study groups.

	PEG GCSF group	GCSF group	P-value
Headache	-	-	-
Flue like syndrome	-	20%	0/024
Bone pain	13/3%	26/7%	0/197
Fever	33/3%	20%	0/243

ONLINE SUBMISSION

www.ijps.ir